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ABSTRACT
Aims/Introduction: Type 2 diabetes is characterized by progressive deterioration of b-
cell function. Recently, it was suggested that the C-peptide-to-glucose ratio after oral glu-
cose ingestion is a better predictor of b-cell mass than that during fasting. We investi-
gated whether postprandial C-peptide-to-glucose ratio (PCGR) reflects b-cell function, and
its clinical application for management of type 2 diabetes.
Materials and Methods: We carried out a two-step retrospective study of 919 Korean
participants with type 2 diabetes. In the first step, we evaluated the correlation of PCGR
level with various markers for b-cell function in newly diagnosed and drug-na€ıve patients
after a mixed meal test. In the second step, participants with well-controlled diabetes
(glycated hemoglobin <7%) were divided into four groups according to treatment
modality (group I: insulin, group II: sulfonylurea and/or dipeptityl peptidase IV inhibitor,
group III: metformin and/or thiazolidinedione and group IV: diet and exercise group).
Results: In the first step, PCGR was significantly correlated with various insulin secretory
indices. Furthermore, PCGR showed better correlation with glycemic indices than homeo-
static model assessment of b-cell function (HOMA-b). In the second step, the PCGR value
significantly increased according to the following order: group I, II, III, and IV after adjusting
for age, sex, body mass index and duration of diabetes. The cut-off values of PCGR for
separating each group were 1.457, 2.870 and 3.790, respectively (P < 0.001).
Conclusions: We suggest that PCGR might be a useful marker for b-cell function and
an ancillary parameter in the choice of antidiabetic medication in type 2 diabetes.
INTRODUCTION
Although many leading organizations emphasize individualized
glycemic targets and treatment to lower glucose according to
speciﬁc patient characteristics, the current algorithms of antihy-
perglycemic therapy in type 2 diabetes are based on treatment
modality only considering the fasting and random blood
glucose concentration, which are represented by glycated hemo-
globin (HbA1c), in individual patients1–3. It remains controver-
sial to select ﬁrst-line drugs to treat diabetic patients, even
though metformin is a preferred ﬁrst-line drug. In addition,
there is no consensus to approach the most effective treatment
for an individual patient. Because most patients have already
experienced substantial loss of b-cell function at the time of
diagnosis of type 2 diabetes4,5, it is more reasonable to select
initial antidiabetic medications or modify drugs with consider-
ation for b-cell function of individual patients.
Type 2 diabetes is characterized by insulin resistance and
impaired insulin secretion6. Although insulin resistance shows lit-
tle variation among patients with type 2 diabetes, pancreatic
b-cell function declines progressively over time. The United
Kingdom Prospective Diabetes Study (UKPDS) and the Belfast
Diet Study have shown that progressive loss of b-cell function is
a major cause of hyperglycemia and is also related to treatment
failure of diabetes7,8. In this regard, not only the evaluation of
secular changes in insulin secretion, but also accurate methods to
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evaluate b-cell function are important for management of diabe-
tes9. C-peptide, which is cleaved from insulin in secretory gran-
ules, is a well-known marker for b-cell function10,11. In contrast
to other indices for insulin secretion, C-peptide evaluation is able
to assess b-cell function even in patients undergoing insulin ther-
apy. Recently, it was suggested that the C-peptide-to-glucose ratio
after oral glucose ingestion might be a better marker for pancre-
atic b-cell mass than fasting measures, such as the homeostatic
model assessment of b-cell function (HOMA-b)11.
Thus, we investigated the clinical signiﬁcance of serum post-
prandial C-peptide-to-glucose ratio (PCGR) measurements in
providing indices for insulin secretion and in discriminating
treatment modalities for patients with type 2 diabetes.
MATERIALS AND METHODS
Patients and Study Design
Patients in the diabetes registry of Severance Diabetes Center
between June 2009 and April 2011 were investigated in the
present study. Type 2 diabetic patients aged older than
20 years were included. The exclusion criteria were severe liver
or kidney disease, thyroid disorders, pregnancy, glucocorticoid
therapy, heavy alcoholics and any malignancy including hema-
tological disorders. Our investigation was a retrospective two-
step study. In the ﬁrst step, we investigated whether PCGR
showed a signiﬁcant correlation with indices for insulin secre-
tion function, such as HOMA-b, as well as with indices for
glycemic control. We analyzed 361 newly diagnosed type 2 dia-
betes patients who were drug-na€ıve, and had undergone a
mixed meal test between June 2009 and April 2011. These
participants included most of the patients described in our pre-
vious study12. The test was a standardized liquid meal test
(Ensure; Meiji Dairies Corporation, Tokyo, Japan; 500 kcal,
17.5 g fat [31.5%], 68.5 g carbohydrate [54.5%] and 17.5 g pro-
tein [14.0%]) after overnight fasting. Blood samples were
collected at 0 and 90 min (basal and stimulated levels, respec-
tively) for glucose, insulin and C-peptide analyses. We used
fasting glucose, postprandial glucose, glycated albumin (GA)
and HbA1c as the glycemic indices. For the insulin secretory
indices, we used fasting or postprandial C-peptide (FCP or
PCP), delta C-peptide (DCP), fasting C-peptide-to-glucose ratio
(FCGR) or PCGR, insulinogenic index (IGI), index for C-pep-
tide (ICI) and HOMA-b.
In the second step, we assessed the validity of PCGR as a
predictor in the choice of antidiabetic therapy. For this, we ana-
lyzed 558 type 2 diabetic patients who achieved target glycemic
control (HbA1c <7.0%), and had constant antidiabetic medica-
tion for at least 3 months between November 2009 and April
2011. The patients were analyzed retrospectively and divided
into four groups according to their treatment modality
(group I: exogenous insulin, group II: insulin secretagogues
[sulfonylurea (SU) and/or dipeptidyl dipeptidase IV inhibitor
(DPPIVi)], group III: insulin sensitizer [metformin (Met) and/
or thiazolidinedione (TZD)], and group IV: lifestyle modiﬁca-
tion [diet and exercise (D&E)]), based on the treatments’
strength and differential function on glycemic reduction. We
ﬁrst evaluated whether PCGR levels were signiﬁcantly different
among the groups. Subsequently, we investigated the cut-off
values of PCGR for discriminating each medication group. To
evaluate the validity of the cut-off values of PCGR, a training
set comprising of randomly selected cases (70% of the partici-
pants) was used to select an optimal cut-off, which was then
tested on the independent left-out validation set (30% of the
participants). The blood samples for plasma glucose and C-pep-
tide were obtained after an overnight fasting and 2 h after an
individually composed breakfast. The study protocol was
approved by the ethics committee of the Severance Hospital.
According to the International Conference on Harmonization
Good Clinical Practice (ICH GCP) guidelines13, all information
was recorded in a manner so that participants could not be
identiﬁed and kept in a locked computer.
Biochemical Test
Plasma glucose levels were measured using the glucose oxidase
method and a Hitachi 747 automatic analyzer (Hitachi Instru-
ments Service, Tokyo, Japan). Serum GA levels were measured
using the enzymatic method and a Hitachi 7699 P module
autoanalyzer (Hitachi Instruments Service, Tokyo, Japan).
HbA1c levels were measured by high-performance liquid chro-
matography using a Variant II Turbo (Bio-Rad Laboratories,
Hercules, CA, USA). Serum insulin and C-peptide levels were
measured in duplicate by immunoradiometric assay (Beckman
Coulter, Fullerton, CA, USA). DCP was calculated as (C-peptide
90 min - C-peptide 0 min). HOMA-b was calculated as fasting
insulin (lIU/mL) 9 20 / fasting glucose (mmol/L) - 3.5.
The IGI was calculated as (insulin 90 min - insulin
0 min) / (glucose 90 min - glucose 0 min), while the corre-
sponding ICI was (C-peptide 90 min - C-peptide
0 min) / (glucose 90 min - glucose 0 min). FCGR and PCGR
were calculated as (fasting or postprandial C-peptide level [ng/
mL] / fasting or postprandial glucose level [mg/dL] 9 100).
Statistical Analysis
Analysis of variance (ANOVA) or analysis of covariance (ANCOVA)
tests was used to compare variables. All continuous variables
are shown as the mean – standard deviation except for ANCOVA
analysis (mean – standard error). To compare the relationship
among HbA1c, GA and other variables, Pearson’s correlation
coefﬁcients were used to assess the associations between clinical
and laboratory variables. We analyzed the differences in the
correlated coefﬁcients between PCGR or HOMA-b and glyce-
mic indices using Steiger’s Z-test. The receiver operating char-
acteristic (ROC) curve of PCGR was shown, and the area
under the curve (AUC) was calculated for separating each med-
ication group. To determine the optimal cut-off value, the point
on the ROC curve with maximum Youden index (sensitiv-
ity + speciﬁcity – 1) was calculated. Statistical analyses were
carried out using SAS version 9.2 (SAS Institute, Cary, NC,
USA). A P-value <0.05 was considered signiﬁcant.
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RESULTS
Correlations Between Variable Indices of b-Cell Function
The baseline characteristics of the newly diagnosed type 2 dia-
betic patients are shown in Table 1. From the ﬁrst step analysis,
the correlation between PCGR and insulin secretory indices
widely accepted as predictors for b-cell function was investi-
gated in 361 drug-na€ıve patients with newly presenting type 2
diabetes (Table 2). Among these indices, PCP, DCP and PCGR
showed a signiﬁcant correlation with previously established
insulin secretory indices, such as IGI, ICI and HOMA-b. The
PCGR showed a stronger correlation with HOMA-b
(r = 0.552, P < 0.001) than PCP and DCP (r = 0.370,
r = 0.307, respectively, all P < 0.001). Although FCGR had a
moderately strong correlation (0.6–0.8) with HOMA-b
(r = 0.705, P < 0.001), FCGR did not have any correlation
with IGI or ICI. As expected, IGI showed a very strong correla-
tion (at least 0.8) with ICI (r = 0.928, P < 0.001). However,
neither IGI nor ICI showed any correlation with HOMA-b. A
partial correlation adjusted for age, sex and body mass index
(BMI) showed similar results among various insulin secretory
indices.
Correlations of PCGR and HOMA- b with Glycemic Indices
During the ﬁrst step analysis to ﬁnd an effective insulin secre-
tory index predicting well-controlled glycemia, we compared
the correlations of indices for insulin secretion, such as
PCGR or HOMA-b, with various glycemic indices, such as fast-
ing and postprandial glucose, glycated albumin and HbA1c.
Overall, both indices showed a good correlation with glycemic
indices (Figure 1). Although PCGR was calculated using post-
prandial indices, including C-peptide and glucose level, PCGR
(r = -0.558, P < 0.001) showed a strong correlation with fast-
ing glucose levels, which was shown in HOMA-b (r = -0.587,
P < 0.001). Additionally, PCGR showed signiﬁcantly stronger
correlations with GA and HbA1c (r = -0.602 with GA and
r = -0.591 with HbA1c, all P < 0.001) than HOMA-b did
(r = -0.521 with GA, and r = -0.471 with HbA1c, all
P < 0.001).
Clinical Characteristics of Participants According to
Antidiabetic Medications
In the second step analysis, we hypothesized that the patients
who had achieved target glycemic control (HbA1c <7%) might
have received appropriate antidiabetic therapy according to
their b-cell secretory function. To investigate whether PCGR
can differentiate treatment modalities in type 2 diabetes, we
analyzed 558 patients with type 2 diabetes under good glycemic
control (HbA1c <7%). Table 3 shows the signiﬁcantly different
fasting and postprandial glucose levels among groups that were
divided according to treatment modalities. As expected, the
insulin-treated group I showed lower C-peptide level (both
FCP and PCP) and longer duration of disease than the other
medication groups. In contrast to FCGR level, mean PCGR lev-
els were signiﬁcantly different among groups, and decreased
according to the following order: group IV (D&E), group III
(Met/TZD), group II (SU/DPPIVi) and group I (insulin;
Table 3 and Figure 2). The different PCGR levels among
groups were still signiﬁcant after adjusting for age, sex, BMI
and duration of disease (Figure 2).
Cut-off Values of PCGR for Discriminating Antidiabetic
Medication groups
We hypothesized that different types of treatment modalities
could be differentiated by PCGR levels in patients with good
glycemic control, and determined the cut-off values of PCGR
for distinguishing between treatment modalities, such as
SU/DPPIVi, Met/TZD and D&E. From the training set (70%
of the participants), the PCGR cut-off value for discriminating
between group I (insulin) and group II (SU/DPPIVi) was 1.457
(AUC 0.763, 95% conﬁdence interval [CI] 0.67-0.86) with
92.6% sensitivity and 60.0% speciﬁcity; between group II (SU/
DPPIVi) and group III (Met/TZD) was 2.870 (AUC 0.634,
95% CI 0.58-0.69) with 75.5% sensitivity and 51.4% speciﬁcity;
between group III (Met/TZD) and group IV (D&E) was 3.790
(AUC 0.593, 95% CI 0.53-0.66) with 69.5% sensitivity and
49.1% speciﬁcity (Figure 3 and Supplementary Table 1). In the
validation set (the remaining 30% of the participants), the sen-
sitivity and speciﬁcity of PCGR cut-off value were 81.0% and
41.7% between group I (insulin) and group II (SU/DPPIVi),
73.9% and 44.4% between group II (SU/DPPIVi) and group III
(Met/TZD), and 70.5% and 52.2% between group III (Met/
TZD) and group IV (D&E), respectively.
Table 1 | Characteristics of 361 newly diagnosed, drug-n€aive type 2
diabetic patients
Variables
Male:female 140:221
Age (years) 55.3 – 11.0
BMI (kg/m2) 25.24 – 3.39
HbA1c (%) 7.3 – 1.8
Glycated albumin (%) 17.8 – 7.3
FPG (mg/dL) 127.3 – 42.4
PPG (mg/dL) 197.1 – 86.5
FCP (ng/mL) 2.23 – 0.82
PCP (ng/mL) 6.78 – 3.11
DCP 4.57 – 2.88
FCGR 1.86 – 0.75
PCGR 3.99 – 2.14
IGI 1.14 – 3.16
ICI 0.11 – 0.31
HOMA-b 59.35 – 31.82
DCP, postprandial C-peptide; BMI, body mass index; FCGR, fasting
C-peptide-to-glucose ratio; FCP, fasting C-peptide; FPG, fasting plasma
glucose; HbA1c, glycated hemoglobin; HOMA-b, homeostasis model
assessment of b-cell function; ICI, C-peptide-genic index; IGI, insulino-
genic index; PCGR, postprandial C-peptide-to-glucose ratio; PCP, post-
prandial C-peptide; PPG, postprandial plasma glucose.
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DISCUSSION
Insulin resistance is observed in more than 80% of type 2 dia-
betes patients with little variation14. In contrast, pancreatic b-
cell mass decreases progressively during the course of diabetes,
which results in signiﬁcantly decreased insulin secretory capac-
ity7,15,16. Because glucose control in diabetes is closely associated
with pancreatic b-cell mass, it is important to identify predic-
tors of pancreatic b-cell function in patients with type 2 diabe-
tes. In Asian populations, inadequate b-cell response to
increasing insulin resistance is considered as the cause of loss
of glycemic control and increased risk of diabetes, even with
relatively little weight gain17. For this reason, the typical charac-
teristic of Korean patients with type 2 diabetes in the develop-
ment and aggravation of hyperglycemia is secretory b-cell
dysfunction18. The oral glucose tolerance test and HOMA indi-
ces have been commonly applied as functional tests for insulin
secretion19,20. However, the interpretation of insulin concentra-
tions is complicated, because insulin levels should be not only
matched with glucose concentrations, but also borne in mind
in the situation of insulin use. Although HOMA is often used
in large clinical and epidemiological studies, it is not suitable
for some diabetic patients because of hyperglycemic state or
Table 2 | Correlation between postprandial C-peptide-to-glucose ratio and insulin secretory indices
FCP PCP DCP FCGR PCGR IGI ICI HOMA-b
FCP - 0.419** 0.169* 0.788** 0.198** 0.085 0.037 0.319**
PCP - 0.967** 0.506** 0.732** 0.218** 0.180** 0.370**
DCP - 0.313** 0.742** 0.212** 0.181** 0.307**
FCGR - 0.538** 0.103 0.080 0.705**
PCGR - 0.277** 0.256** 0.552**
IGI - 0.928** 0.082
ICI - 0.094
HOMA-b -
FCP† - 0.392** 0.155* 0.757** 0.196** 0.047 0.014 0.280**
PCP† - 0.970** 0.489** 0.738** 0.212** 0.171* 0.357**
DCP† - 0.324** 0.740** 0.215** 0.180* 0.309**
FCGR† - 0.557** 0.075 0.062 0.706**
PCGR† - 0.276** 0.256** 0.561**
IGI† - 0.929** 0.064
ICI† - 0.085
HOMA-b† -
*P < 0.01, **P < 0.001, derived from Pearson’s correlation. †Pearson’s partial correlation adjusted for age, sex and body mass index. DCP, postpran-
dial C-peptide; FCGR, fasting C-peptide-to-glucose ratio; FCP, fasting C-peptide; HOMA-b, homeostasis model assessment of b-cell function; ICI,
C-peptide-genic index; IGI, insulinogenic index; PCGR, postprandial C-peptide-to-glucose ratio; PCP, postprandial C-peptide.
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Figure 1 | Correlations between postprandial C-peptide-to-glucose ratio (PCGR) or homeostatic model assessment of b-cell function (HOMA-b) and
glycemic indices. HbA1c, glycated hemoglobin.
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insulin use. In addition, a recent study measuring b-cell area in
humans showed that there was no relationship between
HOMA-b and b-cell area11.
Postprandial insulin deﬁciency is regarded as the main
explanatory factor of deteriorating glucose control in newly
developed type 2 diabetes21. A study showed that the reduc-
tion of postprandial insulin secretion is more prominent than
that of fasting insulin secretion in the progression of type 2
diabetes22. It was thus suggested that postprandial b-cell func-
tion might be a more important factor for glycemic control
than fasting b-cell function. Although there are many studies
on indices for insulin secretory function, only a few studies
have investigated staged management of type 2 diabetes based
on insulin secretory function using these indices. Furthermore,
the studies were only able to distinguish which patients
require insulin therapy based on the indices23,24. Recently,
PCGR after oral glucose ingestion was suggested to be a bet-
ter predictor for the b-cell area, the region responsible for b-
cell function, than fasting measures11. Therefore, we used a
new, expanded practical index, PCGR, for assessing insulin
secretion as part of a new therapeutic strategy for individu-
alized treatment for type 2 diabetes. To precisely analyze
the relationship between endogenous insulin secretion and
the various markers, we carried out a standardized mixed
meal test in newly diagnosed, drug-na€ıve type 2 diabetic
patients. PCGR values were correlated with other insulin
secretory indices, such as HOMA-b, IGI and ICI (Table 2).
Additionally, PCGR showed a strong correlation with glyce-
mic indices including plasma glucose level and glycated
index for glycemic control (HbA1c and GA) than HOMA-
b (Figure 1). These results suggest that PCGR might be
used as an index for insulin secretion in practical ﬁelds. In
addition, PCGR is easily calculated using postprandial
C-peptide and glucose levels measured at the time of diag-
nosis for type 2 diabetic patients.
In the present study, we categorized diabetic patients with
good glycemic control based on their maintained antidiabetic
medication. As shown in Figure 2, PCGR levels after adjusting
for age, sex, BMI and duration of disease were different accord-
ing to the medication group (2.27 – 0.28, 3.32 – 0.11,
3.89 – 0.13, 4.53 – 0.14 for group I (insulin), group II (SU/
DPPIVi), group III (Met/TZD) and group IV (D&E), respec-
tively, P < 0.001 for ANCOVA). We also obtained the cut-off
values of PCGR to distinguish each treatment group in patients
with well-controlled glycemic level from the training set and ver-
iﬁed that in the validation set. From the analysis of the training
set, the cut-off values of PCGR for discriminating between
treatment groups were 1.457, 2.870 and 3.790, respectively (all
P < 0.001; Figure 3). In the validation set, the sensitivity of the
PCGR cut-off value was maintained as relatively constant,
although the speciﬁcity of that was low. We suggest that these
cut-off values could be applied when choosing antidiabetic
agents for patients with type 2 diabetes. In accordance with the
present results, recent studies have shown that PCGR is also a
better predictor of future insulin therapy than fasting C-peptide
index25,26. PCGR is a simple and practical marker for insulin
secretion, and it can be helpful in determining appropriate
treatment modalities, such as insulin, insulin secretagogues (SU
and/or DPPIVi), insulin sensitizer (Met and/or TZD) and life-
style modiﬁcation. As plasma glucose is the most potent stimu-
lator of insulin secretion, it is presumed that PCGR level
reﬂects b-cell function more precisely than FCGR or plasma C-
peptide level itself does. Furthermore, insulin secretion is more
impaired in the postprandial state than in the fasting state7,
and it is stimulated by high plasma glucose level and incretin
hormone27. Thus, PCGR index might be a more useful
Table 3 | Characteristics of 558 patients with well controlled glycemia according to medication groups
Group I (Insulin) Group II (SU/DPPIVi) Group III (Met/TZD) Group IV (D&E) P-value†
n 42 211 156 149
Male : female 32:10 105:106* 86:70* 86:63* 0.016
Age (years) 60.0 – 13.5 65.7 – 9.8* 63.0 – 10.2§ 58.5 – 10.3§– <0.001
BMI (kg/m2) 23.22 – 2.90 24.37 – 2.94* 24.91 – 3.03* 24.21 – 3.37 0.021
Duration 8.8 – 1.5 7.2 – 0.6* 6.4 – 0.5*§ 4.1 – 0.3*§– <0.001
HbA1c (%) 8.02 – 2.05 7.12 – 1.46* 6.73 – 0.86*§ 6.17 – 0.48*§– <0.001
HbA1c (%)‡ 6.5 – 0.4 6.4 – 0.4 6.5 – 0.3 6.3 – 0.4*§– <0.001
FPG (mg/dL) 140.8 – 69.1 128.4 – 38.7* 119.5 – 25.0*§ 112.6 – 18.8*§ <0.001
PPG (mg/dL) 238.6 – 116.2 209.5 – 69.7* 174.1 – 49.0*§ 154.1 – 47.1*§– <0.001
FCP (ng/mL) 1.34 – 1.23 2.17 – 0.93* 2.20 – 1.14* 2.06 – 0.83* <0.001
PCP (ng/mL) 3.32 – 1.99 6.03 – 2.62* 6.75 – 2.69*§ 6.91 – 2.45*§ <0.001
FCGR 1.12 – 1.27 1.82 – 0.92* 1.94 – 1.32* 1.85 – 0.77* <0.001
PCGR 1.63 – 1.25 3.17 – 1.61* 4.05 – 1.61*§ 4.71 – 1.67*§– <0.001
*P < 0.05 vs insulin group. †P-values by v2-test or ANOVA are provided for the four-group comparisons. ‡Glycated hemoglobin (HbA1c) when
achieved target glycemic control (HbA1c <7%). §P < 0.05 vs sulfonylurea/dipeptidyl peptidase IV inhibitor (SU/DPPIVi) group, –P < 0.05 vs metfor-
min/thiazolidinedione (Met/TZD) group. CGR, fasting C-peptide-to-glucose ratio; D&E, diet and exercise; F/U, follow up; FCP, fasting C-peptide; FPG,
fasting plasma glucose; PCGR, postprandial C-peptide-to-glucose ratio; PCP, postprandial C-peptide; PPG, postprandial plasma glucose.
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predictor of b-cell function than other indices measured during
the fasting state.
The limitations of the present study were as follows. First,
the study was based on retrospective analysis. Based on the
results from the present study, a prospective study is in
progress. Second, we did not examine glucagon-stimulated
C-peptide levels, which is one of the most widely used meth-
ods for insulin secretory functions of diabetic patients28,29. In
addition, the C-peptide levels could have been inﬂuenced or
modiﬁed by the medications in the second step analysis. For
instance, prolonged treatment with sulfonylurea could have
reduced C-peptide, whereas prolonged treatment with TZD
could have increased b-cell mass. For this reason, a prospec-
tive study of drug-na€ıve patients is in progress, based on
PCGR value. Third, we did not include meglitinide in the
present study, although we suggest the use of similar cut-off
values of PCGR as in group II (SU/DPPIVi), especially for
patients with high postprandial glucose. Fourth, we could not
separately assess the additional effects of insulin sensitizer
(Met or TZD) in group I (insulin) or group II (SU/DPPIVi),
although 76.4% of patients in the present study had already
been treated with additional insulin sensitizers, such as Met
or TZD. Finally, the different cut-off values of PCGR should
be investigated in different ethnic populations. Despite these
limitations, we were able to differentiate treatment modalities
of well-controlled type 2 diabetic patients with PCGR, and
this value can be a useful marker in the determination of
antidiabetic therapy.
In conclusion, the PCGR index might be used as a marker of
insulin secretion and be used as an ancillary parameter for select-
ing antidiabetic medication, as well as insulin therapy in type 2
diabetic patients, based on their individual b-cell functions.
Further prospective study will be warranted to assess the useful-
ness of the PCGR index for staged diabetic management.
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in the patients according to medication groups (a) before and (b) after
adjusting for age, body mass index, and duration of diabetes. *P < 0.05
vs insulin group; †P < 0.05 vs sulfonylurea/dipeptidyl peptidase IV
inhibitor (SU/DPPIVi) group; ‡P < 0.05 vs metformin/thiazolidinedione
(Met/TZD) group. D&E, diet and exercise.
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Figure 3 | Receiver operating characteristic (ROC) curves of
postprandial C-peptide-to-glucose ratio (PCGR) for classifying each
medication group. Area under the curve (AUC) of 0.763 (95%
confidence interval [CI] 0.671-0.855) for group I (insulin) vs group II
(sulfonylurea/dipeptidyl peptidase IV inhibitor [SU/DPPIVi]), 0.634 (95%
CI 0.577-0.691) for group II (SU/DPPIVi) vs group III (metformin/
thiazolidinedione [Met/TZD]) and 0.593 (95% CI 0.529-0.658) for
group III (Met/TZD) vs group IV (diet and exercise [D&E]). The cut-off
values of PCGR were 1.457 with 92.6% sensitivity and 60.0% specificity
for group I (insulin) vs group II (SU/DPPIVi), 2.870 with 75.5% sensitivity
and 51.4% specificity for group II (SU/DPPIVi) vs group III (Met/TZD),
and 3.790 with 69.5% sensitivity and 49.1% specificity for group III (Met/
TZD) vs group IV (D&E).
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Medicine for providing statistical support to the analysis of data
for this research.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article:
Appendix S1 | Cut-off values of postprandial C-peptide-to-glucose ratio (PCGR) for discriminating each medication group in the
training (randomly selected 70% of the participants) and validation (the remaining 30% of the participants) set.
524 J Diabetes Invest Vol. 5 No. 5 September 2014 ª 2014 The Authors. Journal of Diabetes Investigation published by AASD and Wiley Publishing Asia Pty Ltd
O R I G I N A L A R T I C L E
Lee et al. http://onlinelibrary.wiley.com/journal/jdi
